Inna P. Gladysheva

Contact:

University of Arizona College of Medicine - Phoenix 475 North 5th Street, Suite E820, Phoenix, AZ 85004
Research Professor, Research Series
Research Professor, Research Series - Internal Medicine
Faculty
Internal Medicine

Education

  • Postdoctoral Research Fellowship: Cardiovascular Biology and Diseases, Harvard University, School of Public Health, 2004
  • Research Fellowship: Targeted Drug Delivery, Moscow State University, 2001
  • PhD: Biokinetic and Catalyze, Moscow State University, 1994
  • MS: Chemistry, Lomonosov Moscow State University, 1989

Publications

  • Gladysheva, I.P.*, Sullivan, R.D. & Reed, G.L.* (2023). Falling corin and ANP activity levels accelerate development of heart failure and cardiac fibrosis. Front Cardiovasc Medicine. Vol. 10, 1120487., 04/18/2023 - Article, Refereed Journal -
  • Gladysheva, I.P., Sullivan, R.D. & Pellicori, P. (2023). Editorial: Edema in heart failure with reduced ejection fraction. Front Cardiovasc Med . Vol. 10, 1141937., 02/07/2023 - Article, Refereed Journal -
  • Gladysheva, I.P.*, Sullivan, R.D., Ramanathan, K. & Reed, G.L. (2022). Soluble (Pro)Renin Receptor Levels Are Regulated by Plasma Renin Activity and Correlated with Edema in Mice and Humans with HFrEF. Biomedicines, 10(8), 1874, Special Issue Advances in Therapy for Heart Failure., 08/03/2022 - Article, Refereed Journal -
  • Hernandez, M., Sullivan, R.D., McCune, M.E., Reed, G.L. & Gladysheva, I.P. (2022). Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion. Diagnostics, 12, 989, Special Issue Diagnosis and Management of Heart Failure., 04/2022 - Article, Refereed Journal -
  • Gladysheva, I.P.*, Sullivan, R.D. & Reed, G.L.* (2021). Neprilysin and Corin in HF: Does Combining 2 Biomarkers Double Our Insights?. JACC: Heart Failure 9 (5) 406., 05/2021 - Other -
  • Tripathi R., Sullivan, R.D., Fan, T-H.M., Mehta, R.M., Gladysheva, I.P.* & Reed, G.L.* (2021). A Low-Sodium Diet Boosts Ang (1–7) Production and NO-cGMP Bioavailability to Reduce Edema and Enhance Survival in Experimental Heart Failure. Int. J. Mol. Sci. 22(8), 4035. Special Issue Heart Failure: From Molecular Basis to Therapy.2.0., 04/2021 - Article, Refereed Journal -
  • Tripathi, R.^, Sullivan, R.D.^, Fan, T-H.M., Mehta, R.M., Gladysheva, I.P.* & Reed, G.L.* (2020). In Experimental Dilated Cardiomyopathy Heart Failure and Survival Are Adversely Affected by a Lack of Sexual Interactions. Int. J. Mol. Sci. 2020, 21(15), 5450. Special Issue "Genetics and Molecular Pathogenesis of Non-ischemic Cardiomyopathies"., 07/2020 - Article, Refereed Journal -
  • Tripathi, R., Sullivan, R.D. , Fan, T-H.M., Houng, A.K., Mehta, R.M., Reed, G.L.* & Gladysheva, I.P.* (2020). Cardiac-Specific Overexpression of Catalytically Inactive Corin Reduces Edema, Contractile Dysfunction, and Death in Mice with Dilated Cardiomyopathy. Int. J. Mol. Sci. 2020, 21(1), 203. Special Issue Biomolecular Mediators in Cardiomyopathies., 01/2020 - Article, Refereed Journal -
  • Sullivan, R.D. , Mehta, R.M., Tripathi, R., Gladysheva, I.P.* & Reed, G.L.* (2019). Normalizing Plasma Renin Activity in Experimental Dilated Cardiomyopathy: Effects on Edema, Cachexia, and Survival. Int. J. Mol. Sci. 2019, 20(16), 3886. Special Issue Heart Failure: From Molecular Basis to Therapy., 08/2019 - Article, Refereed Journal -
  • Sullivan, R.D., Mehta, R.D., Tripathi, R., Reed, G.L.* & Gladysheva, I.P.* (2019). Renin Activity in Heart Failure with Reduced Systolic Function-New Insights. Int J Mol Sci. Vol. 20, 3182., 06/2019 - Article, Refereed Journal -
Research Interests
- Heart Failure - Cardiomyopathy
Research Summary
Research is focused on the molecular and pathophysiologic mechanisms of cardiomyopathy, heart failure, and concurrent complications in order to delay or prevent the transition from cardiac dysfunction (cardiomyopathy) to symptomatic heart failure characterized by edema and cachexia/sarcopenia. Specifically, we are interested in proteases and hormones as potential diagnostic and therapeutic targets and pharmacological and other approaches (lifestyle choices) to slow progression to heart failure.